US 9,957,263 B2 · Bromodomain inhibitors

Abstract

Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided. The compounds are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Pharmaceutical compositions comprised of one or more compounds of formula (I) are also provided.

Claims5

Dependent claims

A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of

N-{3-[cyclohexyl(methyl)amino]propyl }-4-[2-(2,6-dimethylphenoxy)-5-(methylsulfonyl)phenyl]-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
and
4-[2-(2,4-difluorophenoxy)-5-(methylsulfonyl)phenyl]-6-methyl-2-[(4-methyl-2-phenylpiperazin-1-yl)methyl]-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one.

A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of

4-[2-(2,6-dimethylphenoxy)-4-{(1-phenylpropan-2-yl)[3-(pyrrolidin-1-yl)propyl]carbamoyl}phenyl]-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
4-{4-[(cyanomethyl)(1-phenylpropan-2-yl)carbamoyl]-2-(2,6-dimethylphenoxy)phenyl}-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
4-{4-[(cyanomethyl)(2-phenylpropyl)carbamoyl]-2-(2,6-dimethylphenoxy)phenyl}-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
4-{4-[(3-chlorophenyl)(cyanomethyl)carbamoyl]-2-(2,6-dimethylphenoxy)phenyl}-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
4-{4-[(4-chlorophenyl)(cyanomethyl)carbamoyl]-2-(2,6-dimethylphenoxy)phenyl}-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
4-[4-{[2-(diethylamino)ethyl](2-methylphenyl)carbamoyl}-2-(2,6-dimethylphenoxy)phenyl]-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3 -c]pyridine-2-carboxamide;
4-[4-{(cyanomethyl)[3-(trifluoromethyl)phenyl]carbamoyl}-2-(2,6-dimethylphenoxy)phenyl]-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
4-[4-{cyclohexyl[3-(dimethylamino)propyl]carbamoyl}-2-(2,6-dimethylphenoxy)phenyl]-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
4-{4-[benzyl(4-chlorobenzyl)carbamoyl]-2-(2,6-dimethylphenoxy)phenyl}-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
4-[4-{[2-(dimethylamino)ethyl](pyrimidin-2-yl)carbamoyl}-2-2,6-dimethylphenoxy)phenyl]-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
4-{4-[(3-chlorophenyl)(2-cyanoethyl)carbamoyl]-2-(2,6-dimethylphenoxy)phenyl}-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
4-{4-[(2-cyanoethyl)(cyclohexyl)carbamoyl]-2-(2,6-dimethylphenoxy)phenyl}-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
4-{4-[(cyanomethyl)(phenyl)carbamoyl]-2-(2,6-dimethylphenoxy)phenyl}-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
4-[4-{[2-(diethylamino)ethyl](2-methoxyphenyl)carbamoyl}-2-(2,6-dimethylphenoxy)phenyl]-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
4-[4-{[2-(dimethylamino)ethyl](phenyl)carbamoyl}-2-(2,6-dimethylphenoxy)phenyl]-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
ethyl 4-[{3-(2,6-dimethylphenoxy)-4-[2-(ethylcarbamoyl)-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl]benzoyl}(phenyl)amino]butanoate;
4-[4-{[2-(dimethylamino)ethyl](pyridin-2-yl)carbamoyl}-2-(2,6-dimethylphenoxy)phenyl]-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
4-[4-{[2-(diethylamino)ethyl](phenyl)carbamoyl}-2-(2,6-dimethylphenoxy)phenyl]-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
4-{4-[(cyanomethyl)(4-methoxyphenyl)carbamoyl]-2-(2,6-dimethylphenoxy)phenyl}-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
4-{4-[butyl(2-cyanoethyl)carbamoyl]-2-(2,6-dimethylphenoxy)phenyl}-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
4-[4-{[2-(dimethylamino)ethyl](2-fluoropyridin-4-yl)carbamoyl}-2-(2,6-dimethylphenoxy)phenyl]-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide;
and
4-{4-[cyclohexyl(phenyl)carbamoyl]-2-(2,6-dimethylphenoxy)phenyl}-N-ethyl-6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide.

20 more elements

Dependencies are inferred from the claim text.

Facts

Application

14/392,201Filed 27 Jun 2014 · continuation in part

Priority

28 Jun 2013

Published

US 2016/0272630 A122 Sep 2016

Granted

1 May 2018

Term ends

Not estimatedThe source records don’t support an estimate.

Classification56 codes

C07D 471/04
In which the condensed system contains two hetero rings: ortho-condensed systems
A61K 31/437
Ortho- or peri-condensed with heterocyclic ring systems: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring…
A61K 31/4545
Containing further heterocyclic ring systems: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/496
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: non-condensed piperazines…

Abstract

Facts

Application

14/392,201Filed 27 Jun 2014 · continuation in part

Priority

28 Jun 2013

Published

US 2016/0272630 A122 Sep 2016

Granted

1 May 2018

Term ends

Not estimatedThe source records don’t support an estimate.

Classification56 codes

C07D 471/04
In which the condensed system contains two hetero rings: ortho-condensed systems
A61K 31/437
Ortho- or peri-condensed with heterocyclic ring systems: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring…
A61K 31/4545
Containing further heterocyclic ring systems: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/496
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: non-condensed piperazines…

Bromodomain inhibitors

Life of this patent

Abstract

Claims5

Bromodomain inhibitors

Life of this patent

Abstract

Claims5